Article

Haemangiopericytoma of the thyroid gland in combination with Hashimoto's disease.

Institute of Pathology, Johannes Gutenberg, University of Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany. .
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin (Impact Factor: 2.56). 10/2004; 445(3):315-9. DOI: 10.1007/s00428-004-1066-5
Source: PubMed

ABSTRACT We present a hitherto unique case of haemangiopericytoma (HP) of the thyroid gland in a 15-year-old female patient suffering from Hashimoto's disease for several months. Since angiogenesis has been discussed to play a major role in both diseases, we examined the expression of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). Most interestingly, strong expression of PDGFR alpha and beta was found in spindle-shaped tumour cells and tumour vessels in HP, while VEGF and VEGFR type I and -II were negative in these regions. In contrast, VEGF was expressed in the lymphoid infiltrate of Hashimoto's disease. Since PDGFR-beta is commonly expressed in pericytes, we suggest that the strong expression discovered in this study further supports the view that HP is derived from pericytes. The combination of HP and Hashimoto's disease is most probably a coincidental event. However, this case confirms previous reports demonstrating that in patients with Hashimoto's disease different neoplasias can occur.

0 Bookmarks
 · 
98 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China A patient with a seven-year history of recurrent metastatic hemangiopericytoma (HPC) was admitted. During his treatment, he received surgical resection, radiotherapy, radiofrequency hyperthermia and chemotherapy using combined doxorubicin, dacarbazin, vincristine, ginsenoside Rg3, and recombinant human endostatin. This synergistic method provides an encouraging model for treating HPC.
    Cancer biology & medicine. 06/2012; 9(2):141-143.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oncogenic osteomalacia is a rare metabolic bone disease characterized by phosphaturia and hypophosphatemia. Certain tumors secrete a phosphaturic factor, which results in this metabolic abnormality; this factor called as phosphatonin, is in fact a fibroblast growth factor 23 (FGF-23) involved closely in phosphate homeostasis and skeletogenesis. Complete excision of these tumors facilitates reversal of the problem. We have reported here the case of a patient who was crippled with this disease and on thorough investigation revealed an oncogenic osteomalacia with tumor focus in the right tibia. The tumor was identified as a mesenchymal tumor, i.e., hemangiopericytoma. Tumor excision alleviated patient symptoms with rapid symptomatic and biochemical improvement.
    Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India. 10/2011; 26(4):188-91.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oncogenic osteomalacia is a rare metabolic bone disease characterized by hypophosphatemia, renal phosphate wasting, suppressed 1,25-dihydroxyvitamin D production, and osteomalacia. A phosphaturic factor secreted by these tumors is responsible for the symptomatology. The main mechanism underlying this disease condition is an over expression of fibroblast growth factor 23 (FGF-23). Complete excision of these tumors facilitates successful reversal of the problem. We report the case of a patient who was crippled and on extensive investigation revealed an oncogenic osteomalacia with tumor focus in right tibia. The tumor was identified as a mesenchymal tumor, i.e. hemangiopericytoma. Tumor excision alleviated patient symptoms with rapid symptomatic and biochemical improvement.
    Fooyin Journal of Health Sciences 08/2010; 2(3):109-112.

Full-text (2 Sources)

Download
76 Downloads
Available from
May 22, 2014